News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The launch of HULIO in the United States is an important milestone for Biocon Biologics
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
